Sally Gene Tamayo, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Uniformed Services University Of The Health Sciences F. Edward Hébert School Of Medicine - Bethesda MD
Rank: Associate Professor
Years: 2005 - present

None Reported

Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clinical Cardiology
Volume: 38
Date: 02 2015
https://doi.org/10.1002/clc.22373

Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation
Journal of the American College of Cardiology
Volume: 68
Date: 09 2016
https://doi.org/10.1016/j.jacc.2016.06.028

Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice
Thromb Haemost
Volume: 116
Date: 09 2016
DOI: 10.1160/TH16-06-0485

Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
American Journal of Cardiology
Volume: 119
Date: 03 2017
DOI: 10.1016/j.amjcard.2016.11.023

CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban.
Annals of Emergency Medicine
Volume: 69
Date: 05 2017
https://doi.org/10.1016/j.annemergmed.2016.09.032

A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban.
Curr Med Res Opin
Volume: 33
Date: 09 2017
DOI: 10.1080/03007995.2017.1351935

Successful treatment of community-acquired methicillin-resistant Staphylococcus aureus purulent myopericarditis.
BMJ Case Reports
Date: 10 2017
DOI: 10.1136/bcr-2017-221931

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation.
Clin Exp Emerg Med
Volume: 30
Date: 03 2018
DOI: 10.15441/ceem.17.216